Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire posts positive phase III data for Firazyr

Shire posts positive phase III data for Firazyr

6th August 2010

Shire has published data from new clinical trials of Firazyr (icatibant), its new drug for the treatment of hereditary angioedema (HAE) attacks.

The pharmaceutical company recently conducted a pair of phase III clinical trials which evaluated the efficacy of the drug among adult patients with type 1 or type 2 HAE, both in isolation and compared to placebo.

It was found that Shire’s therapy was able to demonstrate effectiveness in reducing abdominal and cutaneous pain, as well as providing relief against laryngeal attacks.

Professor Marco Cicardi of the department of internal medicine at the University of Milan said these benefits were important due to the “unpredictability and variability” of the disease.

He added: “The publication of this study shows the subcutaneous injection of icatibant to be an effective and well-tolerated treatment for acute attacks of HAE in adults.”

Earlier this week, Shire published its financial report for the third quarter, announcing a 35 per cent year-on-year increase in revenues.ADNFCR-8000103-ID-800015152-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.